% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gambichler:285235,
      author       = {T. Gambichler and M. Iordanou and J. C. Becker$^*$ and L.
                      Susok},
      title        = {{I}ntratumoural and systemic inflammation as predictors for
                      treatment response in {BRAF}-mutated melanoma patients under
                      targeted therapies.},
      journal      = {Melanoma research},
      volume       = {34},
      number       = {1},
      issn         = {0960-8931},
      address      = {[Erscheinungsort nicht ermittelbar]},
      publisher    = {Ovid},
      reportid     = {DKFZ-2023-02270},
      pages        = {80-83},
      year         = {2024},
      note         = {2024 Feb 1;34(1):80-83 / Short communication},
      abstract     = {Intratumoural as well as systemic inflammation in melanoma
                      has thoroughly been studied in the context of patients
                      treated with immune checkpoint inhibitors but not with
                      BRAF/MEK inhibitors (BRAFi/MEKi). We aimed to study whether
                      parameters of intratumoral and systemic inflammation
                      correlate with clinical outcome in patients with BRAF-mutant
                      metastatic melanoma treated with BRAFi/MEKi. We studied 51
                      CM patients with unresectable stage III or IV who had the
                      indication for BRAFi/MEKi treatment based on confirmed BRAF
                      mutation. Baseline systemic immune-inflammation markers such
                      as the systemic immune-inflammation index (SII) and the
                      expression of intratumoral inflammation markers such as
                      COX-2 protein expression were correlated with clinical
                      outcome measures. On multivariable analyses, lower
                      intratumoral COX-2 expression (OR 33.9, $95\%$ CI 3.2-356.8)
                      and lower SII (OR 6.3, $95\%$ CI 1.1-34.8) proved to be
                      significant independent predictors for objective response to
                      targeted therapy. Elevated S100B (HR 1.2, $95\%$ CI
                      1.03-1.3) was a significant predictor for progressive
                      disease. Moreover, elevated S100B (HR 1.37, $95\%$ CI
                      1.14-1.65) and LDH (HR 1.002, $95\%$ CI 1.0001-1.003) were
                      significant independent predictors for melanoma-specific
                      death. In conclusion, the present study indicates that low
                      SII values and low intratumoral COX-2 protein expression are
                      significant independent predictors for treatment response to
                      BRAFi/MEKi.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37924529},
      doi          = {10.1097/CMR.0000000000000934},
      url          = {https://inrepo02.dkfz.de/record/285235},
}